Thalidomide as a potent inhibitor of neointimal hyperplasia after balloon injury in rat carotid artery.

OBJECTIVE Inflammation is one of the main pathogeneses of neointimal hyperplasia after coronary intervention. Thalidomide, because of its potent antiinflammatory and immunomodulatory properties, is being re-evaluated in several clinical fields. Therefore, we examined whether thalidomide therapy affects neointimal formation. METHODS AND RESULTS In male Sprague-Dawley rats, 100 mg/kg of either thalidomide or sucrose (control) was administered daily from 3 days before injury to 2 weeks after conventional carotid artery denudation injury. Thalidomide administration resulted in a significant reduction of neointimal formation (neointima to media ratio 1.26+/-0.29 versus 0.35+/-0.13, P<0.001) and proliferative activity of vascular smooth muscle cells. In addition, arterial macrophage infiltration and local expressions of tumor necrosis factor alpha (TNF-alpha) and basic fibroblast growth factor (bFGF) in the injured arteries as measured by immunohistochemistry and immunoblot analysis were significantly reduced by thalidomide treatment. Serum TNF-alpha, measured by ELISA, was also significantly reduced in the thalidomide-treated animals compared with controls after injury (856+/-213 versus 449+/-68 pg/mL on day 3, P=0.001; 129+/-34 versus 63+/-18 pg/mL on day 14, P=0.001), and we observed a good positive correlation between the serum TNF-alpha levels and the severity of neointimal growth. CONCLUSIONS We found that thalidomide, through its antiinflammatory and antiproliferative effects, significantly inhibits neointimal hyperplasia in balloon-injured rat carotid arteries. Our results suggest a potential role of thalidomide as a potent inhibitor of neointimal formation after angioplasty.

[1]  R. Finnell,et al.  Molecular basis of environmentally induced birth defects. , 2003, Annual review of pharmacology and toxicology.

[2]  Pedro A. Lemos,et al.  Drug‐Eluting Stents: Cost Versus Clinical Benefit , 2003, Circulation.

[3]  D. Kereiakes.  Hippocrates revisited: the evidence for drug-eluting stents. , 2003, Circulation.

[4]  Rossella Fattori,et al.  Drug-eluting stents in vascular intervention , 2003, The Lancet.

[5]  M. Eisenberg,et al.  Coated Stents for the Prevention of Restenosis: Part II , 2002, Circulation.

[6]  S. Frøland,et al.  Effect of thalidomide in patients with chronic heart failure. , 2002, American heart journal.

[7]  F. Welt,et al.  Inflammation and Restenosis in the Stent Era , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[8]  A. Gershlick,et al.  Tumor necrosis factor-alpha antibody eluting stents reduce vascular smooth muscle cell proliferation in saphenous vein organ culture. , 2002, Experimental and molecular pathology.

[9]  B. Bozkurt,et al.  Preclinical and clinical assessment of the safety and potential efficacy of thalidomide in heart failure. , 2002, Journal of cardiac failure.

[10]  P. Serruys,et al.  Persistent Inhibition of Neointimal Hyperplasia After Sirolimus-Eluting Stent Implantation: Long-Term (Up to 2 Years) Clinical, Angiographic, and Intravascular Ultrasound Follow-Up , 2002, Circulation.

[11]  E. Edelman,et al.  Systemic Inflammation Induced by Lipopolysaccharide Increases Neointimal Formation After Balloon and Stent Injury in Rabbits , 2002, Circulation.

[12]  K. Sugimachi,et al.  Essential Role of Monocyte Chemoattractant Protein-1 in Development of Restenotic Changes (Neointimal Hyperplasia and Constrictive Remodeling) After Balloon Angioplasty in Hypercholesterolemic Rabbits , 2002, Circulation.

[13]  P. Amouyel,et al.  The 5A6A polymorphism in the promoter of the stromelysin-1 (MMP3) gene as a risk factor for restenosis. , 2002, European heart journal.

[14]  B. Aggarwal,et al.  Thalidomide Suppresses NF-κB Activation Induced by TNF and H2O2, But Not That Activated by Ceramide, Lipopolysaccharides, or Phorbol Ester1 , 2002, The Journal of Immunology.

[15]  E. Topol,et al.  Effect of anti-tumor necrosis factor-alpha polyclonal antibody on restenosis after balloon angioplasty in a rabbit atherosclerotic model. , 2002, Atherosclerosis.

[16]  P. Kloetzel,et al.  Ubiquitin-Proteasome Pathway as a New Target for the Prevention of Restenosis , 2002, Circulation.

[17]  M. Davis,et al.  Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vitro treatment with the anti-TNF-alpha agent thalidomide. , 2001, Cellular and molecular biology.

[18]  A. Miller,et al.  Inflammation As A Key Event In The Development Of Neointima Following Vascular Balloon Injury , 2001, Clinical and experimental pharmacology & physiology.

[19]  M. Hecker,et al.  Thalidomide impairment of trinitrobenzene sulphonic acid‐induced colitis in the rat–role of endothelial cell‐leukocyte interaction , 2001, British journal of pharmacology.

[20]  G. Martinelli,et al.  Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  L. Khachigian,et al.  Acute Local Release of Fibroblast Growth Factor-2 but not Transforming Growth Factor-β1 following Coronary Stenting , 2001, Thrombosis and Haemostasis.

[22]  F. Amalric,et al.  Uncoupling of cell proliferation and differentiation activities of basic fibroblast growth factor , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[23]  N. Raje,et al.  Thalidomide--a revival story. , 1999, The New England journal of medicine.

[24]  E. Topol,et al.  Frontiers in interventional cardiology. , 1998, Circulation.

[25]  A. Peri,et al.  Potential roles of osteopontin and αVβ3 integrin in the development of coronary artery restenosis after angioplasty , 1997 .

[26]  J. Zweier,et al.  Coronary angioplasty results in leukocyte and platelet activation with adhesion molecule expression. Evidence of inflammatory responses in coronary angioplasty. , 1997, Journal of the American College of Cardiology.

[27]  R. D'Amato,et al.  Thalidomide is an inhibitor of angiogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[28]  P. Libby,et al.  Sustained Activation of Vascular Cells and Leukocytes in the Rabbit Aorta After Balloon Injury , 1993, Circulation.

[29]  M. Reidy,et al.  Expression of basic fibroblast growth factor and its receptor by smooth muscle cells and endothelium in injured rat arteries. An en face study. , 1993, Circulation research.

[30]  G. Kaplan,et al.  Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation , 1993, The Journal of experimental medicine.

[31]  H. Granger,et al.  Internalized basic fibroblast growth factor translocates to nuclei of venular endothelial cells. , 1992, The American journal of physiology.

[32]  E. Edelman,et al.  Basic fibroblast growth factor enhances the coupling of intimal hyperplasia and proliferation of vasa vasorum in injured rat arteries. , 1992, The Journal of clinical investigation.

[33]  P. Cuevas,et al.  Vascular response to basic fibroblast growth factor when infused onto the normal adventitia or into the injured media of the rat carotid artery. , 1991, Circulation research.

[34]  M. Reidy,et al.  Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[35]  G. Kaplan,et al.  Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes , 1991, The Journal of experimental medicine.

[36]  J. Teissié,et al.  Basic fibroblast growth factor enters the nucleolus and stimulates the transcription of ribosomal genes in ABAE cells undergoing G0----G1 transition. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Ousa,et al.  A RANDOMIZED COMPARISON OF A SIROLIMUS-ELUTING STENT WITH A STANDARD STENT FOR CORONARY REVASCULARIZATION , 2002 .

[38]  H. Bergmeister,et al.  Artery Balloon Angioplasty Model B Significantly Contributes to Lumen Loss in a Rabbit Iliac κ Activation of Nuclear Factor , 2002 .

[39]  S. Mousa,et al.  Selective alpha(v)beta(3)-receptor blockade reduces macrophage infiltration and restenosis after balloon angioplasty in the atherosclerotic rabbit. , 2001, Circulation.

[40]  W. Mcbride,et al.  Interaction of [glutarimide-2-14C]-thalidomide with rat embryonic DNA in vivo. , 1997, Teratogenesis, carcinogenesis, and mutagenesis.

[41]  P. Libby,et al.  Proliferating arterial smooth muscle cells after balloon injury express TNF-alpha but not interleukin-1 or basic fibroblast growth factor. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[42]  N. Jönsson.  Chemical structure and teratogenic properties. IV. An outline of a chemical hypothesis for the teratogenic action of thalidomide. , 1972, Acta pharmaceutica Suecica.